An updated Cost-effectiveness analysis of Pazopanib Versus Sunitinib as First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma in Italy.
CONCLUSIONS: Pazopanib is likely to represent a cost-effective treatment option compared with sunitinib as a first-line treatment for patients with metastatic RCC in Italy.
PMID: 33079593 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research
More News: Cancer & Oncology | Carcinoma | Economics | Health Management | Italy Health | Kidney Cancer | Renal Cell Carcinoma | UK Health